Oramed to Start Pivotal Phase 3 Oral Insulin Studies

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company is about to start their Phase 3 Studies for their oral insulin candidate drug, ORMD-0801. The ORMD-0801 has…

Continue Reading Oramed to Start Pivotal Phase 3 Oral Insulin Studies